Transcriptomics

Dataset Information

0

Etrolizumab treatment in Crohn's disease (Bergamot) cohort 1 RNA-seq


ABSTRACT: Etrolizumab is an investigational monoclonal antibody that binds the β7 subunit of α4β7 and αEβ7 integrins. The relative contribution of α4β7 and αEβ7 to gut lymphocyte trafficking remains to be characterized. Here we show that αEβ7 is highly expressed on human intestinal CD8+ cytotoxic intraepithelial lymphocytes (IELs) and a small subset of proinflammatory CD4+ T cells. Dual blockade of α4β7 and αEβ7 reduced CD8+ T cell accumulation in the gut to a greater extent than single blockade of either pathway using a photo-convertible mouse model. αEβ7 blockade decreased T cell-epithelial interactions, increased the migratory speed and promoted egress of activated T cells. In Crohn’s disease patients treated with etrolizumab, a reduction of inflammatory genes and cytotoxic IEL gene signatures was observed. Concurrent blockade of α4β7 and αEβ7 increases reduction of cytotoxic IELs and inflammatory T cells in the gut mucosa through a stepwise inhibition of cell migration and tissue retention. The "SAMPLE_ID" sample characteristic is a sample identifier internal to Genentech.

ORGANISM(S): Homo sapiens

PROVIDER: GSE152316 | GEO | 2021/07/23

REPOSITORIES: GEO

Similar Datasets

2023-11-17 | GSE236922 | GEO
2018-07-10 | E-MTAB-6510 | biostudies-arrayexpress
2023-11-01 | GSE193534 | GEO
2023-11-01 | GSE193593 | GEO
2023-11-01 | GSE219087 | GEO
2011-09-06 | GSE29980 | GEO
2024-01-13 | GSE252762 | GEO
2023-07-14 | GSE228838 | GEO
2020-10-02 | GSE157453 | GEO
2016-11-23 | E-MTAB-4960 | biostudies-arrayexpress